Charles River Laboratoriesvs.IQVIA Holdings
CRL vs IQV · both in CDMO & pharma manufacturing, part of the Medicine, pharma & life science value chain: Contract development and manufacturing of medicines — the industrial backbone behind the drugs.
IQVIA Holdings is about 3.1× larger than Charles River Laboratories by market cap; year to date, Charles River Laboratories leads (+17.0% vs −7.8%).
Side by side
| CRL | IQV | |
|---|---|---|
| Market cap | $11.3B | $34.6B |
| Price | $233.41 | $207.85 |
| Today | −0.1% | −0.5% |
| Return YTD | +17.0% | −7.8% |
| Return 1Y | +42.6% | +25.6% |
| P/E | — | 25.0 |
| P/S | 2.8 | 2.1 |
| P/B | 3.8 | 5.6 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Charles River LaboratoriesCRL
American provider of preclinical research and testing services for pharma and biotech — models and laboratory services throughout drug development.
Full CRL profile →IQVIA HoldingsIQV
Clinical research (CRO) and healthcare data analytics for the pharmaceutical industry.
Full IQV profile →More comparisons in CDMO & pharma manufacturing
See where CRL and IQV sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →